首页> 外文OA文献 >Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

【2h】

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

机译：oLaparib用于维持BRCA 1或2突变，复发，铂敏感的卵巢，输卵管和腹膜癌的人们，其复发疾病的患者对铂族化疗作出反应：证据审查集团的观点，对一个良好的单一技术评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Paul Tappenden; Sue Harnan; Shijie Ren; Praveen Thokala; Ruth Wong; Clara Mukuria; Clare Green; Simon Pledge; John Tidy;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer [J] . Tucker Helen, Charles Zoe, Robertson Janet, The lancet oncology . 2016,第3期

机译：NICE关于奥拉帕尼对复发，铂敏感，BRCA突变阳性卵巢癌患者的维持治疗的指南
2. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial [J] . Friedlander Michael, Gebski Val, Gibbs Emma, The lancet oncology . 2018,第8期

机译：在铂敏感，复发卵巢癌和BRCA1 / 2突变患者中，在化疗后，与奥拉帕里韦维持的健康相关的生活质量和患者为中心的结果（Solo2 / engot OV-21）：安慰剂控制，第3期随机试验
3. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial [J] . Friedlander Michael, Gebski Val, Gibbs Emma, The lancet oncology . 2018,第8期

机译：在铂敏感，复发卵巢癌和BRCA1 / 2突变患者中，在化疗后，与奥拉帕里韦维持的健康相关的生活质量和患者为中心的结果（Solo2 / engot OV-21）：安慰剂控制，第3期随机试验
4. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [O] . Tosin Lambe, Rui Duarte, James Mahon, -1

机译：克拉屈滨片用于复发-缓解型多发性硬化症的一线治疗：NICE单项技术评估的证据审查组观点
5. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [O] . Tappenden P., Harnan S., Ren S., 2016

机译：Olaparib用于维持治疗BRCa 1或2突变，复发，铂敏感的卵巢，输卵管和腹膜癌的患者，其复发疾病已对铂类化疗有反应：证据评估组对NICE单一技术评估的观点

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

著录项

引文网络

相似文献

相关主题

期刊订阅